Hunan Jiudian Pharmaceutical Co Ltd banner

Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705

Watchlist Manager
Hunan Jiudian Pharmaceutical Co Ltd Logo
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Watchlist
Price: 12.84 CNY -0.62% Market Closed
Market Cap: ¥6.4B

EV/S

2
Current
30%
Cheaper
vs 3-y average of 2.9

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2
=
Enterprise Value
¥7.5B
/
Revenue
¥3.1B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2
=
Enterprise Value
¥7.5B
/
Revenue
¥3.1B

Valuation Scenarios

Hunan Jiudian Pharmaceutical Co Ltd is trading below its 3-year average

If EV/S returns to its 3-Year Average (2.9), the stock would be worth ¥18.45 (44% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+72%
Average Upside
55%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 2 ¥12.84
0%
3-Year Average 2.9 ¥18.45
+44%
5-Year Average 2.9 ¥18.41
+43%
Industry Average 3.5 ¥22.03
+72%
Country Average 3.3 ¥20.85
+62%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥7.5B
/
Oct 2025
¥3.1B
=
2
Current
¥7.5B
/
Dec 2025
¥3.6B
=
2.1
Forward
¥7.5B
/
Dec 2026
¥4.1B
=
1.8
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CN
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
6.4B CNY 2 13.7
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 12.8 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 5.9 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 5.1 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 5.1 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 4.7 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 3.2 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 3.1 16.4

Market Distribution

In line with most companies in China
Percentile
34th
Based on 7 593 companies
34th percentile
2
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Hunan Jiudian Pharmaceutical Co Ltd
Glance View

Market Cap
6.4B CNY
Industry
Pharmaceuticals

Hunan Jiudian Pharmaceutical Co Ltd, nestled amidst the vibrant commercial landscape of China, exemplifies the dynamic evolution of the pharmaceutical industry within the region. Founded on the principles of innovation and resilience, the company has carved a niche by focusing on the development, production, and sale of a variety of active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates through an intricate web of research and development that is deeply aligned with the latest advancements in medical science. Central to its operations is a robust R&D facility that not only ensures high-standard quality control but also keeps the pipeline brimming with potential new products. This forward-thinking approach is critical, as it continually feeds the market with pharmaceuticals that cater to both chronic and acute health conditions, ranging from anti-infectives to cardiovascular drugs. The company capitalizes on a vertically integrated business model, which substantially aids in controlling cost and quality across all stages of production. By managing a seamless supply chain that extends from raw material procurement to drug distribution, Hunan Jiudian Pharmaceutical ensures both operational efficiency and market competitiveness. Revenue streams largely flow from the sale of its proprietary products in domestic and international markets, supported by a comprehensive marketing strategy and a broad distribution network. This pragmatic blend of science, strategy, and salesmanship allows the company not only to generate profits but also to contribute significantly to the global pharmaceutical framework, marking its presence as a formidable player in this ever-changing industry.

Intrinsic Value
11.83 CNY
Overvaluation 8%
Intrinsic Value
Price ¥12.84
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett